hero image

Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

May 19, 2016 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that the webcast of the Company's 2016 Annual Meeting of Stockholders will be held on Wednesday, June 8, 2016 at 9:00 a.m. Eastern Daylight Time. A live audio webcast of the meeting will be available on the Investor Relations section of the Company's corporate website at www.biogen.com/investors or directly via www.virtualshareholdermeeting.com/BIIB. An archive of the webcast will be available for replay following the meeting. Please allow at least 10 minutes prior to the event to visit the site and download the necessary software to listen to the webcast.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

 

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

$Cashtags

thumb
May 16, 2024
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of

thumb
May 14, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the